A national survey of the current methods used by specialists to evaluate pituitary function in the UK was performed by postal questionnaire. Seventy-three respondents, of whom 89% were consultants and 80% clinical endocrinologists, returned the questionnaire. Fifty per cent routinely used the insulin stress test (1ST) to evaluate the hypothalamopituitary-adrenal (HPA) axis, while 50% routinely used tetracosactrin stimulation, there being little overlap between the two groups. This represents a significant change in clinical practice since the last survey in 1988. In those who used ACTH stimulation there was almost an equal split into those who administered the tetracosactrin intramuscularly (45%) or intravenously (47%). Furthermore, either the peak or 60 min cortisol value was used by 71% when interpreting the result of the test, despite the fact that in previous studies only the 30 min cortisol value has been shown to correlate with the 1STresult. The 1STremains the most frequently used method to assess growth hormone reserve in adult subjects. The thyrotrophin-releasing-hormone and gonadotrophin-releasing-hormone tests are still used routinely by approximately a quarter of clinicians. These results provide data that could be used to develop guide-lines for the use of tests to investigate pituitary function. 7 Reschini E, Cantania A, Giustina G. Plasma cortisol response to ACTH does not accurately indicate the state of the hypothalamic-pituitaryadrenal axis.] Endocrinol Invest 1982;5:259-61 8 Pavord SR, Girach A, Price DE, Absalom SR, Falconer-Smith 1. Howlett TA, A retrospective audit of the combined pituitary function test, using the insulin stress test, TRH and GnRH in a district laboratory. Clin Endocrin 1992;36:135-9 9 Besser GM, McNeilly AS, Anderson DC, et al. Hormonal responses to synthetic LH and FSH releasing hormones in man. BM] 1972; 3:267-71
INTRODUCTION
Formal bĩchemi cal assessment is essential for the accurate diagnosis of,pypopituitarism. For the last 20 years pituitary function ha; been traditionally assessed by the insulin stress test (1ST) often used in conjunction with releasing-hormone tests'. However, recently this approach has been questioned and some workers have suggested that other methods can be used to investigate pituitary function". These include both the measurement of the basal cortisol level and the response to tetracosactrin (the short synacthen test, SST) [3] [4] [5] A number of studies have shown that the 30 min cortisol response after intravenous or intramuscular tetracosactrin is strongly correlated with the peak cortisol during the 1ST, and it has been suggested that the SST could replace the 1ST as a first line dynamic test for ACTHIcortisol reserve 3 ,4. However, some controversy remains as a small but significant number of discordant results were reported in the two larger studies and in a number of smaller studies and case reports, and it is known that the SST is unreliable within 2 weeks of pituitary surgery or other acute pituitary insults and after recent discontinuation of steroid therapyl:", Department of Endocrinology, Leicester Royal Infirmary, Leicester LEt 5WW,
England Correspondence to: Dr T A Howlett
Parvord et al. in their retrospective study of 2321STs demonstrated the potential value of measuring the basal cortisol level and reported that subjects with a basal cortisol of less than 100 nmol/I, never, and those with a basal level of greater than 400 nmol/I, always, had a normal peak cortisol during the 1ST. If these criteria alone were used, with the aim being to assess only the ACTH / cortisol reserve, then 55% of the ISTs carried out could retrospectively have been avoided''. This study also questioned the use of the thyroid-releasing (TRH) and gonadotrophinreleasing (GnRH) hormone tests which are often used in conjunction with the 1ST, and found that in most cases they provided unhelpful, even misleading, results; in the vast majority of cases measurement of basal thyroid function, luteinizing hormone (LH), follicle stimulating hormone (FSH) and gonadal steroids was suflicient''.
In his 1988 paper, Stewart carried out a small survey of the use of the 1ST and SST to assess pituitary function amongst UK endocrinologists and found that 25% used the SST as a first line dynamic test for ACTH / cortisol reserve", It is in the light of these more recent studies that we felt there was a need to reassess the current usage of dynamic tests in the assessment of pituitary function, particularly to see if there has been a significant change in practice during the last 5 years. This paper presents the results of a national survey of the use of methods to assess pituitary function by a large number of endocrine specialists. exactly the same as those for insulin induced hypoglycaemia, there was considerable polarization regarding the use of these two methods to evaluate the HPA axis with only 11% of respondents routinely using both tests and 8% using neither.
The dose of synacthen used (250/lg) was uniform but there was an almost equal split into those who administered it intravenously (47%) or intramuscularly (45%). Importantly, the timing of the sample of cortisol used to interpret the test varied, with only 29% using the 30 min sample, the sample which has been validated in published studies, 14% the 60 min sample which is usually higher, and 57% using the peak cortisol which usually equates with the 60 min value. There was considerable variation in the normal ranges applied with a peak cortisol ranging from 300-650 nmolll (Figure 2 ), although a peak cortisol concentration of 500-550 nmolll was most often used. 
METHODS
A questionnaire was designed to assess the tests used to investigate pituitary function-the HPA axis, growth hormone (GH) reserve, hypothalamic-pituitary-thyroid function, hypothalamic-pituitary-gonadal function, releasing-hormone tests and dynamic tests to assess prolactin. Colleagues were asked if they 'always', 'usually', 'sometimes', 'rarely' or 'never' used various tests, about the criteria used for interpreting the test, and in some instances the specific method used to conduct the test. For the purposes of this paper 'routine use' refers to those tests used either 'always' or 'usually': if no answer was given it was assumed the test was never used, unless otherwise stated. Each respondent was asked to report the normal range they applied to each test including the lower limit of what they considered to be a normal response.
The questionnaire was circulated in the autumn of 1993 to all those on the mailing list of the Endocrine Section of the Royal Society of Medicine and the Society for Endocrinology which are the major national forums for the presentation and discussion of clinical aspects of endocrinology in the UK. Seventy-three questionnaires were returned. All responses were anonymous but respondents were asked to indicate their clinical grade, speciality (e.g. clinical endocrinologist) and their institution (e.g. teaching or district general hospital); 80% were clinical endocrinologists of whom 89% were consultants and 66% from teaching hospitals. The full mailing list of the Endocrine Society and the Endocrine Section of the RSM totals some 1400 but includes a significant number of members and non-clinical members. Some of those who returned questionnaires were members of both the Endocrine Society and Endocrine Section of the RSM (41%) and involved some duplication.
RESULTS

160P
Hypothalamo-pituitary-adrenal axis
Thirty-seven (50%) of respondents routinely used the 1ST to assess the HPA axis and 14 respondents (19%) sometimes used this method. The dose of insulin most often used to induce hypoglycaemia was 0.15 U/kg although the initial dose given ranged from 0.05 to 0.2 U/kg, with larger doses being used in patients with acromegaly or Cushing's syndrome. Interpretation of the result varied considerably with the normal peak cortisol ranging from 420-580 nmolll, although a peak concentration of 550 nmol/l was most commonly used ( Figure 1 ). Some stated that a normal response should include an incremental rise of 200no nmolll but this was never taken as the sole criterion.
The SST was used by 37 respondents (50%) as routine for the evaluation of the HPA axis and a further 14 sometimes used this method. Although the figures are '" t 20 .... Use of other tests of the HPA axis were considered. The glucagon test was not used by 41 respondents (56%) and only by four respondents (5%) routinely. The metyrapone test was used routinely only by one respondent. A basal serum cortisol level, often stated to be taken at 0900 h, was
Investigation of growth hormone reserve
Insulin induced hypoglycaemia was used most often to evaluate growth hormone reserve in adult patients and 34 of those surveyed (47%) employed it routinely. There was considerable variation in the accepted normal peak level with a range from 4-40 mIll but 20 mUll was the concentration most commonly used (Figure 4 ). In overall clinical practice there was a variety of other methods in routine usc ( Figure  5 ). The practice in children was significantly different with growth velocity used almost uniformly, 25% used exercise stimulation, 25% the glucagon test, 33% the clonidine test, but only 10% used the 1ST routinely. Other tests used to assess growth hormone reserve included overnight urine collections for growth hormone, arginine stimulation either alone or before c1onidine, and measurement of insulin growth factor 1 (IGF-l) and IGF binding protein-3.
Hypothalamo-pitultary-gonadal function
The measurement of basal LH and FSH was used routinely by 95.2% of respondents to investigate both male (93.2%) and female (97.3%) patients. The GnRH test is considered below. Measurement of basal gonadal steroid hormones (i.e. testosterone or oestradiol) was used by 86% of respondents to investigate women and by 96% to investigate men. Sex hormone binding globulin (SHBG) was used less frequently with only 29% of respondents routinely measuring it in women and 19% in men. The clomiphene test was routinely used by 10 respondents (14%), but again there was considerable variation in the accepted normal ranges for both .=Patients with suspected pituitary disease; .=thyroid tests used in routine screening largely due to the work done by Lindholm and Kehlet, and more recently by Stewart, who have shown that the cortisol response 30 min after ACTH stimulation is closely correlated with the peak cortisol response during the IST3,4,1O. There is no doubt that the 1ST is viewed by many as the 'gold standard' for evaluating ACTHI cortisol reserve, even amongst those who routinely use the SST, and has withstood the test of time as a routine clinical test. However, it is inconvenient, causes unpleasant symptoms of hypoglycaemia, is associated with dangerous side effects if poorly supervised and is expensive. Certainly in infants and children particular care needs to be taken with the 1ST and it should only be performed by experienced investigators who give constant supervision throughout the procedure. There is also concern about the use of the SST as a replacement for the 1ST: first, because it has only been validated directly with stressful illness in very small studies; and, secondly, because of the discordant results between the SST and 1ST reported in the larger studies and in a variety of smaller studies and case reports 3-7, I I. Whilst the majority of these discordant results tended to err on the side of safety (i.e, those subjects with a subnormal SST result but an adequate 1STresult), the full significance, incidence and true interpretation of these discordant results have yet to be investigated. There is no doubt that the SST is unable to unreliable for assessing the HPA axis within 2 weeks of pituitary surgery or other acute pituitary insults and after recent discontinuation of steroid therapy3,4. One possible and important explanation for the discordant results observed in some studies may be the timing of the cortisol sample used when interpreting the SST. In both Lindholm's and Stewart's studies only the 30 min cortisol value was correlated with the 1ST response. Our survey would suggest that most (71%) use either the peak cortisol or the 60 min cortisol to define a normal response during the SST, yet it has been shown that the 162P the LH and FSH responses'". Thirteen respondents (18%) used other tests to investigate hypothalamo-pituitary-gonadal function and these included the use of human chorionic gonadotrophin (HCG), human menopausal gonadotrophin and gonadotrophin-releasing hormone analogue stimulation tests.
Releasing-hormone
The GnRH test was used routinely by 24 (27%) respondents, but never by 15 respondents (20.6%). There was, however, a considerable variation in the reported normal ranges; thus if the LH response was considered as a percentage increase from basal, the accepted normal range varied from 50-1000%. Similarly, the TRH test was used routinely by 19 respondents (26%), but never by 21 (29%). Again there was no consensus on normal ranges, with a percentage increase in TSH from 200--600%, an incremental rise from 1-4mU/l, or an absolute rise to a concentration ranging from 4.2 -18mUII being used.
Hypothalamo-pituitary-thyroid function
The use of baseline tests in the context of routine screening of thyroid function and specifically to assess hypothalamopituitary-thyroid function in patients with known or suspected pituitary disease are shown in Figure 6 . There appears to be an increase in the measurement of free T3 and free T4, and a decrease in the measurement of TSH in those patients specifically thought to have pituitary disease when compared to their use as routine screening thyroid function tests.
Dynamic tests to assess prolactin
These were used only by 11 respondents (15%) routinely and never by 47 (64%). The majority used the TRH test although metoclopramide and domperidone stimulation was also used by a few.
DISCUSSION
Methods used to evaluate pituitary function appear to have changed significantly over recent years, with a shift in the choice between the 1ST and SST for first line assessment of the HPA axis. From the results of this survey it is clear that about half of the respondents use the 1ST routinely and the other half the SST, with little overlap between these groups. This impression was amply confirmed at a subsequent 'consensus' meeting of the Endocrine Section of the Royal Society of Medicine in which there was a clear 50: 50 polarization of the audience without clear consensus between the two groups. The increase in the use of the SST as a first line dynamic test for assessment of the HPA axis is probably 60 min cortisol is consistently higher by an average of over 100nmolll than the 30min samplel/. Thus, if the peak (which usually occurs at 60 min) or the 60 min cortisol is used for interpreting the SST, it cannot be assumed that a 'normal response' will show the same close correlation with a 'normal response' in the IST4. This may partly explain some of the discordant results which have been observed, and, more worryingly suggests that a majority of users of the SST in the UK may be using invalid criteria for interpretation. In our view, because of these problems, only the 30 min cortisol value should be used for interpretation of the SST result. It is also of some concern that many workers use intramuscular rather than intravenous tetracosactrin". However, it appears that this difference does not cause a significant difference in the 30 min response, but as the larger studies used intravenous tetracosactrin, for strict comparison, it would seem sensible to use intravenous administration10,12.
Perhaps the most difficult area of pituitary function to assess is growth hormone (GH) reserve. All tests of GH reserve remain controversial and the accepted normal range for GH varied widely between respondents. It has been reported that GH responses vary between tests, between individuals, and even between re-testing the same individual!", In childhood it is now widely recognized that pharmacological tests are of secondary importance to growth velocity. However, the situation in adults is more complex, and altho"h symptoms of growth hormone deficiency in adults arc 6ften non-specific, there is growing support for growth hormone replacement in adults!". All tests have their critics and even the 1ST, previously regarded as the 'gold standard' may not be as reliable as usually assumed; a reliable test of growth hormone reserve still needs to be developed l 5 • The use oflGF-1 in combination with IGF-BP3 taken as a Single basal blood test appears to be a promising option but further experience is required before this becomes routine 16.
The use of the releasing hormone tests remains controversial and the present survey suggests that only a quarter of clinicians continue to use the TRH and GnRH tests as routine in their evaluation of pituitary function. For most workers, it appears that use of these tests has been superseded by more reliable assays for T4, TSH, LH, FSH and gonadal steroids. Furthermore, if we accept that TSH deficiency is reliably diagnosed by a low basal T4 without elevation of TSH, then Parvord et aI. reported that the TRH test produced misleading results in 50% of subjects with a low basal T4 having a 'normal' response to TRH but conversely in those with a subnormal TRH test result only 10% had a low basal T4 8 . The same study revealed similar shortcomings with the GnRH test", The lack of clinical relevance of these tests is further compounded by the fact that no significant publication has established a normal range of hormone responses to these tests in modern assays, a fact highlighted by the complete lack of consensus noted in the survey in the criteria for normal ranges for responses. It would seem sensible to limit the use of releasing hormone tests to very specific clinical situations such as when it is important to determine between a pituitary or hypothalamic cause of hormone deficiency.
This survey reveals that the methods used to evaluate pituitary function are in a stage of transition. Modern assays have allowed precise measurement of the 'end hormones' of all pituitary axes and this appears to have resulted in a decrease in the number of dynamic tests performed. However, in some areas differences in assay techniques and quoted normal ranges mean that consensus on the interpretation of the results of a particular test may be difficult to achieve. The assessment of the HPA axis remains controversial with a broad 50/50 split into those favouring the use of the 1ST or SST. In 1988 Stewart et aI. found that only 25% of endocrinologists used the SST routinely and so it would appear that since then the SST has gained favouri. However the need to validate this test against the response to a subsequent stressful illness, and the increasing need to assess growth hormone reserve in conjunction with ACTHIcortisol reserve are areas which will need further consideration. Collaborative studies would be a major factor in the further assessment of these uncertain areas.
